Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2012, Article ID 542042, 7 pages
http://dx.doi.org/10.1155/2012/542042
Research Article

Sodium-Glucose Cotransporter Inhibition Prevents Oxidative Stress in the Kidney of Diabetic Rats

1Renal Pathophysiology Laboratory, Department of Nephrology, Instituto Nacional de Cardiología “Ignacio Chávez”, Juan Badiano 1, 14080 Mexico City, DF, Mexico
2Health Science Faculty, Universidad Anáhuac, México Norte, 57286 Huixquilucan, State of Mexico, Mexico
3Department of Molecular Biomedicine, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV), 07360 Mexico City, Mexico
4Department of Molecular Biomedicine, CINVESTAV-Monterrey, 66600 Apodaca, NL, Mexico

Received 7 June 2012; Accepted 13 October 2012

Academic Editor: José Luis Martín-Ventura

Copyright © 2012 Horacio Osorio et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [42 citations]

The following is the list of published articles that have cited the current article.

  • Yang Su, Syed M. Qadri, Lingyun Wu, and Lixin Liu, “Methylglyoxal modulates endothelial nitric oxide synthase-associated functions in EA.hy926 endothelial cells,” Cardiovascular Diabetology, vol. 12, 2013. View at Publisher · View at Google Scholar
  • Luke D Boyle, and John PH Wilding, “Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes,” Expert Opinion on Emerging Drugs, vol. 18, no. 3, pp. 375–391, 2013. View at Publisher · View at Google Scholar
  • Qi Wu, Ding-Hua Yi, Shi-Qiang Yu, Jian-Ming Pei, Hai-Yan Wang, Juan Li, Peng Zhou, Qiu-Lin Wang, Lei Zhao, Rong Fan, Yue-Min Wang, and Xue-Zeng Xu, “κ-Opioid Receptor Stimulation Improves Endothelial Function in Hypoxic Pulmonary Hypertension,” PLoS ONE, vol. 8, no. 5, 2013. View at Publisher · View at Google Scholar
  • David Z.I. Cherney, and Bruce A. Perkins, “Sodium-Glucose Cotransporter 2 Inhibition in Type 1 Diabetes: Simultaneous Glucose Lowering and Renal Protection?,” Canadian Journal of Diabetes, 2014. View at Publisher · View at Google Scholar
  • M.C. Thomas, K. Jandeleit-Dahm, and F. Bonnet, “Beyond Glycosuria: Exploring the intrarenal effects of SGLT-2 inhibition in diabetes,” Diabetes & Metabolism, vol. 40, no. 6, pp. S17–S22, 2014. View at Publisher · View at Google Scholar
  • David Z. I. Cherney, Bruce A. Perkins, Nima Soleymanlou, Ronnie Har, Nora Fagan, Odd Erik Johansen, Hans-Juergen Woerle, Maximilian von Eynatten, and Uli C. Broedl, “The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus,” Cardiovascular Diabetology, vol. 13, 2014. View at Publisher · View at Google Scholar
  • Bowen Lin, Nobutaka Koibuchi, Yu Hasegawa, Daisuke Sueta, Kensuke Toyama, Ken Uekawa, MingJie Ma, Takashi Nakagawa, Hiroaki Kusaka, and Shokei Kim-Mitsuyama, “Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice,” Cardiovascular Diabetology, vol. 13, no. 1, pp. 148, 2014. View at Publisher · View at Google Scholar
  • Abraham Said Arellano-Buendía, Fernando Enrique García-Arroyo, Magdalena Cristóbal-García, María Lilia Loredo-Mendoza, Edilia Tapia-Rodríguez, Laura Gabriela Sánchez-Lozada, and Horacio Osorio-Alonso, “Urinary Excretion of Neutrophil Gelatinase-Associated Lipocalin in Diabetic Rats,” Oxidative Medicine and Cellular Longevity, vol. 2014, pp. 1–11, 2014. View at Publisher · View at Google Scholar
  • Julie O'Neill, Angelica Fasching, Liselotte Pihl, Daniela Patinha, Stephanie Franzen, and Fredrik Palm, “Acute SGLT inhibition normalizes O-2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats,” American Journal Of Physiology-Renal Physiology, vol. 309, no. 3, pp. F227–F234, 2015. View at Publisher · View at Google Scholar
  • A. Ojima, T. Matsui, Y. Nishino, N. Nakamura, and S. Yamagishi, “Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy P,” Hormone And Metabolic Research, vol. 47, no. 9, pp. 686–692, 2015. View at Publisher · View at Google Scholar
  • Sho-ichi Yamagishi, and Takanori Matsui, “Protective role of sodium-glucose cotransporter 2 (SGLT2) inhibition against vascular complications in diabetes,” Rejuvenation Research, pp. 150731035046006, 2015. View at Publisher · View at Google Scholar
  • Silvio E. Inzucchi, Bernard Zinman, Christoph Wanner, Roberto Ferrari, David Fitchett, Stefan Hantel, Rosa-Maria Espadero, Hans-Juergen Woerle, Uli C. Broedl, and Odd Erik Johansen, “SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials,” Diabetes & Vascular Disease Research, vol. 12, no. 2, pp. 90–100, 2015. View at Publisher · View at Google Scholar
  • Marko Škrtić, and David Z.I. Cherney, “Sodium–glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy,” Current Opinion in Nephrology and Hypertension, vol. 24, no. 1, pp. 96–103, 2015. View at Publisher · View at Google Scholar
  • Yoshiaki Katsuda, Tomohiko Sasase, Hironobu Tadaki, Yasuko Mera, Yu Motohashi, Yusuke Kemmochi, Kaoru Toyoda, Kochi Kakimoto, Shinichi Kume, and Takeshi Ohta, “Contribution of hyperglycemia on diabetic complications in obese type 2 diabetic SDT fatty rats: effects of SGLT inhibitor phlorizin,” Experimental Animals, vol. 64, no. 2, pp. 161–169, 2015. View at Publisher · View at Google Scholar
  • Gargi Nag, Sukriti Das, Susmita Das, Suvra Mandal, and Bratati De, “Antioxidant, anti-acetylcholinesterase and anti-glycosidase properties of three species of Swertia, their xanthones and amarogentin: A comparative study,” Pharmacognosy Journal, vol. 7, no. 2, pp. 117–123, 2015. View at Publisher · View at Google Scholar
  • Hiddo J.L. Heerspink, David Z. I. Cherney, Bruce A. Perkins, David H. Fitchett, and Mansoor Husain, “Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications,” Circulation, vol. 134, no. 10, pp. 752–772, 2016. View at Publisher · View at Google Scholar
  • Atsushi Tanaka, Toyoaki Murohara, Isao Taguchi, Kazuo Eguchi, Makoto Suzuki, Masafumi Kitakaze, Yasunori Sato, Tomoko Ishizu, Yukihito Higashi, Hirotsugu Yamada, Mamoru Nanasato, Michio Shimabukuro, Hiroki Teragawa, Shinichiro Ueda, Satoshi Kodera, Munehide Matsuhisa, Toshiaki Kadokami, Kazuomi Kario, Yoshihiko Nishio, Teruo Inoue, Koji Maemura, Jun-ichi Oyama, Mitsuru Ohishi, Masataka Sata, Hirofumi Tomiyama, and Koichi Node, “Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study,” Cardiovascular Diabetology, vol. 15, no. 1, 2016. View at Publisher · View at Google Scholar
  • David Cherney, Søren S. Lund, Bruce A. Perkins, Per-Henrik Groop, Mark E. Cooper, Stefan Kaspers, Egon Pfarr, Hans J. Woerle, and Maximilian von Eynatten, “The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes,” Diabetologia, 2016. View at Publisher · View at Google Scholar
  • Atsushi Tanaka, Teruo Inoue, Masafumi Kitakaze, Jun-ichi Oyama, Masataka Sata, Isao Taguchi, Wataru Shimizu, Hirotaka Watada, Hirofumi Tomiyama, Junya Ako, Yasushi Sakata, Toshihisa Anzai, Masaaki Uematsu, Makoto Suzuki, Kazuo Eguchi, Akira Yamashina, Yoshihiko Saito, Yasunori Sato, Shinichiro Ueda, Toyoaki Murohara, and Koichi Node, “Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial,” Cardiovascular Diabetology, vol. 15, no. 1, 2016. View at Publisher · View at Google Scholar
  • Atsushi Tanaka, and Koichi Node, “Emerging roles of sodium–glucose cotransporter 2 inhibitors in cardiology,” Journal of Cardiology, 2016. View at Publisher · View at Google Scholar
  • Yi-Chih Lin, and Shao-Yu Yang, “Benefits and limitations of incretin-based therapies and sodium-glucose transporter 2 inhibitors on diabetic kidney disease,” Journal of Internal Medicine of Taiwan, vol. 27, no. 5, pp. 248–260, 2016. View at Publisher · View at Google Scholar
  • Bruna de Souza Faustino, Alberto dos Reis Costa Junior, L.N.M. Bortolon, L.B.P.C. de Sá, D.R.T.W. Rocha, and Alberto Krayyem Arbex, “The Benefits of SGLT2 Inhibitors in Cardiovascular Prevention, Glycemic Control and Weight Loss, in the Treatment of Diabetes,” Open Journal of Endocrine and Metabolic Diseases, vol. 06, no. 01, pp. 87–94, 2016. View at Publisher · View at Google Scholar
  • José Pedraza-Chaverri, Laura G. Sánchez-Lozada, Horacio Osorio-Alonso, Edilia Tapia, and Alexandra Scholze, “New Pathogenic Concepts and Therapeutic Approaches to Oxidative Stress in Chronic Kidney Disease,” Oxidative Medicine and Cellular Longevity, vol. 2016, pp. 1–21, 2016. View at Publisher · View at Google Scholar
  • Daiji Kawanami, Keiichiro Matoba, Yusuke Takeda, Yosuke Nagai, Tomoyo Akamine, Tamotsu Yokota, Kazunori Sango, and Kazunori Utsunomiya, “SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy,” International Journal of Molecular Sciences, vol. 18, no. 6, pp. 1083, 2017. View at Publisher · View at Google Scholar
  • Atsushi Tanaka, Michio Shimabukuro, Yosuke Okada, Isao Taguchi, Minako Yamaoka-Tojo, Hirofumi Tomiyama, Hiroki Teragawa, Seigo Sugiyama, Hisako Yoshida, Yasunori Sato, Atsushi Kawaguchi, Yumi Ikehara, Noritaka Machii, Tatsuya Maruhashi, Kosuke R. Shima, Toshinari Takamura, Yasushi Matsuzawa, Kazuo Kimura, Masashi Sakuma, Jun-ichi Oyama, Teruo Inoue, Yukihito Higashi, Shinichiro Ueda, and Koichi Node, “Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial,” Cardiovascular Diabetology, vol. 16, no. 1, 2017. View at Publisher · View at Google Scholar
  • Filippatos, Tsimihodimos, Filippas-Ntekouan, and Elisaf, “Renoprotective effects of SGLT2 inhibitors: Beyond glucose reabsorption inhibition,” Current Vascular Pharmacology, vol. 15, no. 2, pp. 96–102, 2017. View at Publisher · View at Google Scholar
  • Joseph A. Messana, Stanley S. Schwartz, and Raymond R. Townsend, “An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes,” Vascular Health and Risk Management, vol. 13, pp. 43–54, 2017. View at Publisher · View at Google Scholar
  • Daisuke Ito, Emi Ikuma-Suwa, Kazuyuki Inoue, Kimie Kaneko, Morifumi Yanagisawa, Kouichi Inukai, Mitsuhiko Noda, and Akira Shimada, “Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study.,” Journal of clinical medicine research, vol. 9, no. 2, pp. 154–162, 2017. View at Publisher · View at Google Scholar
  • Michael E. Røder, “Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential,” Therapeutic Advances in Chronic Disease, pp. 204062231773528, 2017. View at Publisher · View at Google Scholar
  • Mariana R Pioli, Alessandra M V Ritter, and Rodrigo Modolo, “Unsweetening the Heart: Possible Pleiotropic Effects of SGLT2 Inhibitors on Cardio and Cerebrovascular Alterations in Resistant Hypertensive Subjects,” American Journal of Hypertension, vol. 31, no. 3, pp. 274–280, 2017. View at Publisher · View at Google Scholar
  • Ioannis Akoumianakis, and Charalambos Antoniades, “Impaired Vascular Redox Signalling in the Vascular Complications of Obesity and Diabetes Mellitus,” Antioxidants & Redox Signaling, 2017. View at Publisher · View at Google Scholar
  • Krit Jaikumkao, Anchalee Pongchaidecha, Varanuj Chatsudthipong, Siriporn C. Chattipakorn, Nipon Chattipakorn, and Anusorn Lungkaphin, “The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes,” Biomedicine & Pharmacotherapy, vol. 94, pp. 176–187, 2017. View at Publisher · View at Google Scholar
  • Mitchel Tate, David J. Grieve, and Rebecca H. Ritchie, “Are targeted therapies for diabetic cardiomyopathy on the horizon?,” Clinical Science, vol. 131, no. 10, pp. 897–915, 2017. View at Publisher · View at Google Scholar
  • A.K. Pancholia, “Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus,” Indian Heart Journal, 2018. View at Publisher · View at Google Scholar
  • Habib Yaribeygi, Alexandra E. Butler, George E. Barreto, and Amirhossein Sahebkar, “Antioxidative potential of antidiabetic agents: A possible protective mechanism against vascular complications in diabetic patients,” Journal of Cellular Physiology, 2018. View at Publisher · View at Google Scholar
  • Kazuomi Kario, Satoshi Hoshide, Yukie Okawara, Naoko Tomitani, Kenji Yamauchi, Hiroyuki Ohbayashi, Naoki Itabashi, Yuri Matsumoto, and Hiroshi Kanegae, “Effect of canagliflozin on nocturnal home blood pressure in Japanese patients with type 2 diabetes mellitus: The SHIFT-J study,” The Journal of Clinical Hypertension, 2018. View at Publisher · View at Google Scholar
  • Habib Yaribeygi, Stephen L. Atkin, and Amirhossein Sahebkar, “A review of the molecular mechanisms of hyperglycemia-induced free radical generation leading to oxidative stress,” Journal of Cellular Physiology, 2018. View at Publisher · View at Google Scholar
  • Rana Assaly, Diane Gorny, Sandrine Compagnie, Eric Mayoux, Jacques Bernabe, Laurent Alexandre, François Giuliano, and Delphine Behr-Roussel, “The Favorable Effect of Empagliflozin on Erectile Function in an Experimental Model of Type 2 Diabetes,” The Journal of Sexual Medicine, 2018. View at Publisher · View at Google Scholar
  • Ahmed A. Abdelsameea, and Soad L. Kabil, “Mitigation of cisplatin-induced peripheral neuropathy by canagliflozin in rats,” Naunyn-Schmiedeberg's Archives of Pharmacology, 2018. View at Publisher · View at Google Scholar
  • Soad L. Kabil, and Nevertyty M. Mahmoud, “Canagliflozin protects against non-alcoholic steatohepatitis in type-2 diabetic rats through zinc alpha-2 glycoprotein up-regulation,” European Journal of Pharmacology, vol. 828, pp. 135–145, 2018. View at Publisher · View at Google Scholar
  • Beatriz Moreno, Ana Paula de Faria, Alessandra Mileni Versuti Ritter, Lara Buonalumi Tacito Yugar, Silvia Elaine Ferreira-Melo, Rivadavio Amorim, Rodrigo Modolo, André Fattori, Juan Carlos Yugar-Toledo, Antonio Coca, and Heitor Moreno, “Glycated hemoglobin correlates with arterial stiffness and endothelial dysfunction in patients with resistant hypertension and uncontrolled diabetes mellitus,” The Journal of Clinical Hypertension, 2018. View at Publisher · View at Google Scholar
  • Atsushi Kurabayashi, Chiharu Tanaka, Waka Matsumoto, Seiji Naganuma, Mutsuo Furihata, Keiji Inoue, and Yoshihiko Kakinuma, “Murine remote preconditioning increases glucose uptake and suppresses gluconeogenesis in hepatocytes via a brain-liver neurocircuit, leading to counteracting glucose intolerance,” Diabetes Research and Clinical Practice, 2018. View at Publisher · View at Google Scholar